Parallel Advisors’s Solid Biosciences SLDB Stock Holding History

Parallel Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.42K	Buy	197 +72	+58%	+$652	﹤0.01%	3712
2026 Q2	$1.25K	Hold	125	–	–	﹤0.01%	3641
2026 Q1	$900	Hold	125	–	–	﹤0.01%	3559
2025 Q4	$705	Hold	125	–	–	﹤0.01%	3359
2025 Q3	$771	Hold	125	–	–	﹤0.01%	3274
2025 Q2	$609	Buy	125 +118	+1,686%	+$417	﹤0.01%	3284
2025 Q1	$26	Hold	7	–	–	﹤0.01%	3482
2024 Q4	$28	Hold	7	–	–	﹤0.01%	3494
2024 Q3	$49	Hold	7	–	–	﹤0.01%	3359
2024 Q2	$40	Buy	7 +1	+17%	+$9	﹤0.01%	3276
2024 Q1	$80	Hold	6	–	–	﹤0.01%	3217
2023 Q4	$37	Hold	6	–	–	﹤0.01%	3264
2023 Q3	$15	Hold	6	–	–	﹤0.01%	3331
2023 Q2	$31	Hold	6	–	–	﹤0.01%	3325
2023 Q1	$28	Hold	6	–	–	﹤0.01%	3381
2022 Q4	$32	Sell	6 -1	-14%	-$7	﹤0.01%	3303
2022 Q3	$0	Hold	7	–	–	﹤0.01%	3465
2022 Q2	$0	Hold	7	–	–	﹤0.01%	3329
2022 Q1	$0	Buy	+7	New	+$124	﹤0.01%	3248
2021 Q4	–	Sell	-19	Closed	-$1K	–	3274
2021 Q3	$1K	Buy	+19	New	+$807	﹤0.01%	2951

Other funds holding SLDB

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Quantum Private Wealth Tampa, Florida $391M AUM 50.76% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Lido Advisors Los Angeles, California $39.1B AUM 20.96% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Parallel Advisors's SLDB Position: Q3 2026 in Review

Parallel Advisors increased its Solid Biosciences (SLDB) stake by 58% in Q3 2026, buying an estimated $652 and bringing the position to 197 shares worth $1.42K. The position accounts for ﹤0.01% of the portfolio, ranked #3712.

Parallel Advisors first reported a position in SLDB in Q3 2021 and has held it in 20 quarters since. 31 funds tracked by Wall St. Rank hold SLDB as of Q3 2026.

Parallel Advisors held 197 shares of Solid Biosciences worth $1.42K as of Q3 2026.
Parallel Advisors bought 72 Solid Biosciences shares in Q3 2026, an estimated $652.
Solid Biosciences made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3712 holding.
Parallel Advisors first reported a position in Solid Biosciences in Q3 2021 and has held it in 20 quarters since.
31 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.